91高清自产国产拍,无码免费A级毛片大全,日本欧美国产中文字幕,99re热视频这里只有精品视频首页

首页

400-620-6333

提交您使用阿拉丁产品的研究文章，就得100元奖励！立即访问我们的提交页面.

跳到内容

语言

切换导航

我的购物车

搜索

菜单

账号

设置

语言

首页
应用
药物靶标
酶
肽酶和蛋白酶
Osocimab?(anti-Factor XI)

Osocimab?(anti-Factor XI)

功能和特点

规格或纯度: Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
反应种属: Human,Rabbit?
亚型: Human IgG1

有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

货号 (SKU)	包装规格	是否现货
Ab175621-100μg (试用装) 申请此免费试用装（?）作为尊贵的客户，您每年可免费申请三次您选择的不同货号试用装产品，尽享探索与享受！	100μg	期货
Ab175621-1mg	1mg	期货
Ab175621-5mg	5mg	期货
Ab175621-10mg	10mg	期货

查看相关系列

Accession#:P03951 coagulation factor XI Antibody F11 Factor XI Gene ID:2160

Skip to the end of the images gallery

Skip to the beginning of the images gallery

基本信息

产品名称	Osocimab?(anti-Factor XI)
规格或纯度	Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
特异性	F11
反应种属	Human,Rabbit?
偶联标记	Unconjugated

产品属性

克隆	Recombinant
Format	Whole IgG
亚型	Human IgG1
轻链亚型	Kappa
SDS-PAGE	27.0 kDa (Light Chain) & 51.6 kDa (Heavy Chain), under reducing conditions; 186.1 kDa, under non-reducing conditions.
纯化方法	Protein A purified
纯度	>95%
物理外观	Liquid
储存缓冲液	Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂	No
浓度	Lot by Lot
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS编号和信息	2056878-75-0

数据库链接

IMGT/mAb-DB	857

关联配体

Ligand ID	11366
名称	osocimab
别名	BAY1213790
类别	Antibody
学名	4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide
生物活性评价	The sulfonamide class of antibacterial compounds are primarily bacteriostatic agents and have a broad spectrum of activity against both Gram-positive and Gram-negative species of bacteria (reviewed in ).
评价	Osocimab (BAY 1213790) is a fully humanized monoclonal antibody that targets activated Factor XI . It is being investigated for clinical prevention of thrombosis .
单字母多肽序列
三字母多肽序列
翻译后修饰
化学修饰
临床描述	This study was to compare the study drug BAY1213790 to existing therapies, i.e. enoxaparin or apixaban, for the prevention of blood clotting and safety in patients undergoing total knee arthroplasty (TKA). The study was open-label, but observer-blinded for the different doses of BAY1213790. This means that it was known which treatment was given, but it was not known which dose of BAY1213790 was administered. In this study researchers want to learn about the safety of drug Osocimab at low and high doses in adult participants with kidney disease undergoing regular dialysis (a procedure that uses a machine to get rid of toxins and extra fluids in the blood). Patients with kidney disease undergoing regular dialysis are at high risk for heart and blood vessels diseases. Osocimab is a human monoclonal antibody under development for the prevention of events caused by blood clots like heart attack, stroke and death due to heart or blood vessels diseases. It works by binding to and blocking the activated form of clotting factor XI which increases the formation and stability of clots. Researchers also want to find out how drug Osocimab works in human body and how the body absorbs, distributes and excretes the drug. Participants in this study will receive monthly injection of either Osocimab at a low or high dose or placebo (a placebo looks like a treatment but does not have any medicine in it). Both Osocimab and placebo will be injected into the tissue under the skin of the belly. Observation for each participant will last up to 23 months. Blood samples will be collected from the participants to monitor the safety and measure the blood level of the study drug.
来源公司	Bayer Bayer

图片

SEC: Osocimab (anti-Factor XI) (Ab175621)

Osocimab (anti-Factor XI) (Ab175621) - SEC
The purity of Osocimab (anti-Factor XI) (Ab175621) is more than 95% verified by HPLC.

产品问答

登录提交问题

查看全部

您提交该产品问题后,我们会在1-2个工作日内给您答复,您可以登录"我的账号",然后点击"我的产品问答"查看答案

参考文献

1. Schaefer M, Buchmueller A, Dittmer F, Stra?burger J, Wilmen A. (2019) Allosteric Inhibition as a New Mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated Form of Coagulation Factor XI.. J Mol Biol, 431 (24): (4817-4833). [PMID:31655039]
2. Weitz JI, Bauersachs R, Becker B, Berkowitz SD, Freitas MCS, Lassen MR, Metzig C, Raskob GE. (2020) Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial.. JAMA, 323 (2): (130-139). [PMID:31935028]